ANAB Stock Price Chart
ANAB Earnings
AnaptysBio Inc
$66.11
-0.72%
$-0.48
At close: Apr 28, 16:00:00 GMT-4
$66.4
0.43%
$0.29
Pre-market: Apr 29, 05:19:54 GMT-4
Back
AnaptysBio Inc (ANAB) Earnings
Latest Earnings Results: Q4 '25
Reported: 2026-03-03
Historical Earnings
Quarterly
Annual
EPS
Revenue
Earnings FAQ
How did ANAB's recent EPS compare to expectations?
How did AnaptysBio Inc ANAB's revenue perform in the last quarter?
What is the revenue estimate for AnaptysBio Inc?
What's the earning quality score for AnaptysBio Inc?
When does AnaptysBio Inc report earnings?
What are AnaptysBio Inc's expected earnings?
Did AnaptysBio Inc beat earnings expectations?
Key Stats
Prev.Close
$66.59
Open
$67.16
Day's Range
$65.06 - $71.67
52 week range
$15.4 - $69.1
Volume
740.5K
Avg.Volume
556.7K
Dividend yield
--
EPS (TTM)
-0.32
Market Cap
$1.9B
What is ANAB?
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
